Group 1 - The Shanghai Composite Index is at 3625.08 points, above the five-day moving average, with an increase of 0.43% [1] - The total trading volume of A-shares is 820.266 billion yuan [1] - A total of 339 A-shares have prices that have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] Group 2 - The stocks with the highest deviation rates from the five-day moving average include: - Shiyan Institute (300732) with a deviation rate of 15.41% and a daily increase of 20.00% [1] - *ST Tianwei (688511) with a deviation rate of 7.56% and a daily increase of 10.34% [1] - Shenma Electric Power (603530) with a deviation rate of 7.42% and a daily increase of 10.01% [1] - Other stocks with notable performance include: - Hehua Co. (000953) with a deviation rate of 7.39% and a daily increase of 10.01% [1] - Luban Chemical (600727) with a deviation rate of 6.98% and a daily increase of 10.05% [1]

Investment Rating - The industry investment rating is maintained at "Overweight" [4] Core Views - The market performance shows that the Chinese medicine sector has increased by 1.39% last week, while the overall pharmaceutical sector continues its upward trend, with Chinese medicine lagging behind [3][6] - The price governance of traditional Chinese medicine (TCM) is being implemented across multiple regions, with various local health insurance bureaus issuing notifications regarding price risk management for certain TCM products [9] - The valuation metrics for the Chinese medicine sector indicate a PE (ttm) of 28.69X, which has increased by 0.41X week-on-week, and a PB (lf) of 2.37X, which has also risen by 0.03X week-on-week [7] Summary by Sections Market Performance - The Chinese medicine sector reported a closing index of 6638.77 points, reflecting a 1.39% increase, while the overall pharmaceutical index closed at 8580.75 points, up by 1.9% [6][22] - The performance of individual companies within the sector varied, with notable gainers including Zhendong Pharmaceutical and Yabao Pharmaceutical, while Wanbangde and Weikang Pharmaceutical showed declines [6][22] Valuation - The current PE (ttm) for the Chinese medicine sector is 28.69X, with a one-year maximum of 30.13X and a minimum of 22.58X, placing it at the 32.65% percentile since 2013 [7] - The PB (lf) stands at 2.37X, with a one-year maximum of 2.65X and a minimum of 1.99X, positioning it at the 7.04% percentile since 2013 [7] Price Governance - Recent notifications from various local health insurance bureaus indicate a focus on price governance for TCM, with specific measures being taken in regions such as Ningxia and Jilin [9] - The governance aims to address price risks associated with TCM products, particularly those that exceed local minimum treatment costs [9] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11][12] - Specific recommendations include companies with strong R&D capabilities and unique products, as well as those less affected by centralized procurement [12]

New Stock Issuance - New stock issued by Dingjia Precision at a price of 11.16 on July 22, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] - ST Zitian and other companies have also announced new stock issuances[1] Market Alerts - Significant abnormal fluctuations reported for several stocks including Guangshengtang and Huayin Power[1] - Multiple companies have disclosed announcements regarding stock performance and market activities[1] - The report includes links to detailed announcements for various stocks, indicating ongoing market monitoring[1]

Group 1 - Weikang Pharmaceutical's application for the listing of Vitamin K1 drops has been accepted, but it will not impact the company's recent performance due to the uncertainty of the registration approval timeline and results [1] - Samsung Medical's wholly-owned subsidiary has signed an overseas contract worth approximately 341 million RMB, which represents 2.33% of the company's projected revenue for 2024, indicating a strategic move to expand in the Brazilian market [2] - Vili Zhibo plans to list on the Hong Kong Stock Exchange on July 25, with an IPO valuation between 5.958 billion HKD and 6.599 billion HKD, aiming to accelerate clinical development and optimize its technology platform [3] Group 2 - United Pharmaceutical plans to raise over 2.2 billion HKD through a placement of new shares, with proceeds allocated for production facility expansion, external collaborations, and R&D of innovative candidates, highlighting the industry's financing vitality [4] - Jichuan Pharmaceutical's cooperative product, Marcilosavir tablets, has received a drug registration certificate, positioning it as a competitive broad-spectrum antiviral treatment for influenza, which may enhance the company's presence in the anti-infection sector [5]

影响的未公开重大信息； 证券代码：300878 证券简称：维康药业 公告编号：2025-029 浙江维康药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 浙江维康药业股份有限公司（以下简称"公司"）股票连续三个交易日内 （2025年7月17日、2025年7月18日、2025年7月21日）收盘价格涨幅偏离值累计超 过30%，根据深圳证券交易所创业板的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 针对公司股票异常波动情况，公司董事会对公司、控股股东及实际控制人就相 关事项进行了认真核实，现对有关情况说明如下： （http://www.cninfo.com.cn），有关公司的信息均以在上述指定媒体刊登的信息为 准，请广大投资者理性投资，注意风险； 特此公告。 浙江维康药业股份有限公司 董事会 重大事项，也不存在处于筹划阶段的重大事项； 买卖本公司股票； 三、不存在应披露而未披露信息的说明 公司董事会确认，截至本公告披露之日，公司没有任何根据《深圳证券交易所 创业板股票上市规则》等有关规定应予以披露 ...

浙江维康药业股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 证券代码：300878 证券简称：维康药业 公告编号：2025-029 浙江维康药业股份有限公司（以下简称"公司"）股票连续三个交易日内 （2025年7月17日、2025年7月18日、2025年7月21日）收盘价格涨幅偏离值累计超 过30%，根据深圳证券交易所创业板的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 针对公司股票异常波动情况，公司董事会对公司、控股股东及实际控制人就相 关事项进行了认真核实，现对有关情况说明如下： 1、截至本公告日，公司前期披露的信息不存在需要更正、补充之处； 公司董事会确认，截至本公告披露之日，公司没有任何根据《深圳证券交易所 创业板股票上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹 划、商谈、意向、协议等；董事会也未获悉本公司有根据《深圳证券交易所创业板 股票上市规则》等有关规定应予以披露而未披露的、对本公司股票及其衍生品种交 易价格产生较大影响的信息。公司前 ...

A股创新药板块盘初走低，浙江震元跌超6%，莱美药业跌超5%，金城医药、信立泰、神州细胞、维康 药业跟跌。 ...

Group 1: New Energy Sector - Guangnong Sugar Industry's stock surged due to a 260 million yuan targeted issuance aimed at expanding storage logistics and supplementing working capital, indicating real capacity expansion [3] - Hongyuan Green Energy, despite reporting losses, significantly narrowed its loss margin and secured a 20 billion yuan comprehensive credit line, positioning it as a potential future growth stock in the photovoltaic industry [3] - Dongshan Precision's stock rose as its new energy business revenue increased by 36.98% in the first half of the year, and the acquisition of Solstice Optoelectronics allows entry into the core component of AI computing [3] - Xinyi Sheng's net profit is expected to surge by 327% to 385%, with光模块 orders already booked until next year, showcasing a strong combination of sector and performance [3] Group 2: Pharmaceutical Sector - Lisheng Pharmaceutical's stock has seen three consecutive gains, driven by favorable policies for innovative drugs, including the announcement that new drugs will not be subject to centralized procurement [4] - Weikang Pharmaceutical's unique Huangjia Soft Liver Tablets hold an irreplaceable position in liver disease treatment, indicating potential for independent market performance [4] - Caution is advised as pharmaceutical stocks can be volatile, necessitating close monitoring of R&D pipelines and results from medical insurance negotiations [4] Group 3: Robotics Sector - Aowei New Materials has achieved seven consecutive 20% gains, indicating strong market interest despite ongoing risk warnings from the company [4] - The company’s products are utilized in high-end equipment and new energy vehicles, with a recent 6.95% reduction in shareholder numbers suggesting concentrated ownership and long-term investment intentions [4] - Zhejiang Liming, a supplier of precision components for new energy vehicles, has a client list that includes major manufacturers, indicating significant potential for performance growth [4] Group 4: General Market Observations - The market has seen a surge in stocks across various sectors, particularly in new energy, pharmaceuticals, and robotics, reflecting a broader trend of investor enthusiasm [2][4] - Some stocks experiencing rapid gains are ST stocks, which may pose higher risks despite short-term performance boosts due to restructuring or earnings forecasts [4] - Long-term investors are encouraged to focus on companies with sustainable profitability, such as Dongshan Precision and Xinyi Sheng, which benefit from policy support and strong performance [4]

Core Viewpoint - The article highlights the strong performance of the AI computing industry in the A-share market, driven by the resumption of H20 supply from Nvidia and the positive outlook for related sectors such as CPO and PCB [1][3][15]. Group 1: Market Performance - The A-share market has shown a bullish trend, with the Shanghai Composite Index rising by 0.37% and the ChiNext Index increasing by 1.75% [6]. - Key sectors leading the market include aerospace and military, communication equipment, electronic components, and biotechnology, while sectors like electricity and telecommunications have weakened [7][9]. Group 2: AI Computing Sector - The AI computing sector is experiencing high demand, with companies like Xinyiseng seeing a 40% increase in stock price over three days, reflecting strong market sentiment [3][16]. - The CPO sector is particularly favored, with significant capital inflow, amounting to over 320 billion yuan in the second half of 2024, representing 68% of total inflows in the optical module industry [34]. Group 3: Competitive Landscape - Chinese manufacturers hold a competitive edge in the global CPO market, with a market share of 38% compared to 29% for U.S. firms, and over 70% in the 800G segment [26]. - The gross profit margin for Chinese firms ranges from 30% to 35%, outperforming U.S. counterparts by 8-12 percentage points [27]. Group 4: Key Players and Supply Chain - Major Chinese companies like Zhongji Xuchuang and Xinyiseng are crucial suppliers for tech giants such as Nvidia, Meta, and Google, with significant market shares projected for 2025 [30]. - The article emphasizes the importance of technological breakthroughs and supply chain advantages that enable Chinese firms to maintain a competitive position in the AI computing landscape [29]. Group 5: Future Outlook - The resumption of H20 supply and the anticipated growth in AI-related sectors are expected to alleviate previous uncertainties, leading to clearer order visibility and shipment schedules for core suppliers [3][42]. - The overall positive macroeconomic environment, including expectations of interest rate cuts by the Federal Reserve, may shift investor focus towards AI technology as the next major investment opportunity [42].

Market Overview - The A-share market has shown a positive trend with the Shanghai Composite Index rising by 0.37% to 3516.83 points, the Shenzhen Component Index increasing by 1.43% to 10873.62 points, and the ChiNext Index up by 1.75% to 2269.33 points [1] - There is a noticeable increase in foreign investment interest in the Chinese market, with South Korean investors' cumulative trading volume in mainland and Hong Kong stocks exceeding $5.4 billion this year, making China the second-largest overseas investment destination for South Korean investors after the US [1][10] Sector Performance - The computing power, innovative pharmaceuticals, and military sectors have experienced significant gains, with the computing power sector leading the charge [2] - In the computing power sector, companies like Benq Intelligent, Shijia Photon, and Dekeli saw their stock prices rise over 10%, while Cambridge Technology and Changfei Fiber reached their daily limit [2][4] - The innovative pharmaceutical sector remains strong, with companies such as Weikang Pharmaceutical and Maiwei Bio achieving a 20% increase in stock price, and several others rising over 10% [5] Investment Sentiment - Citigroup has upgraded the ratings for Chinese and South Korean stock markets to "overweight," citing a constructive medium-term outlook despite macroeconomic volatility [9] - The report predicts that the Hang Seng Index will reach a target price of 25,000 points by the end of this year and 26,000 points by mid-next year, while the CSI 300 Index is expected to hit 4,200 points by year-end and 4,350 points by mid-next year [9] - In addition, the Invesco Global Sovereign Asset Management Research indicates a rebound in interest from international investment institutions towards the Chinese market, with a total asset management of approximately $27 trillion [12] Future Outlook - The military sector is also gaining traction, with companies like AVIC Shenfei and AVIC Aviation experiencing stock price surges [11] - The recent announcement by NVIDIA to resume supply of the H20 computing power chip for the Chinese market is expected to enhance domestic AI model training and inference capabilities, creating a positive feedback loop for demand [4] - The National Healthcare Security Administration's new policy for innovative drugs aims to balance accessibility and sustainability, indicating a strategic shift in healthcare policy that could benefit the pharmaceutical sector [6]